evolution is presented in the most recent version of the ISCN, published in 2009 [ISCN, 2009]. The world-wide cytogenetic community strives for consistency in the descriptive and interpretive reporting of both normal and abnormal karyotypes, regardless of which technical evaluation method was used. As the field of cytogenetics continues to expand to include several molecular-based technologies, concurrent revisions of cytogenetic nomenclature are critical for accurate descriptions of the new technologies. In addition, as the use of cytogenetics in oncology continues to increase, the use of cytogenetic nomenclature for neoplasms continues to become more well-defined.
the changes are adapted for use in both research and clinical reporting.
This report highlights the major changes in the most current version of the ISCN compared to ISCN [2005] . Karyotype examples are critical for illustrating nomenclature concepts, and new examples given will be noted by ISCN [2009] chapter. Descriptions of changes, with references to corresponding ISCN [2009] sections, can serve as a starting point in understanding and converting to ISCN [2009] nomenclature.
Chapter 2: Normal Chromosomes
One of the most obvious changes in the ISCN [2009] is the re-drawing of many of the idiograms representing chromosomes at various levels of banding resolution. It is important that all cytogeneticists become familiar with these new idiograms, as they contain multiple changes over those originally described by Francke [Francke, 1981] . These new idiograms and their derivation are described by Chia [2009] 
Chapter 5: Uncertainty in Chromosome or Band Designation
A new example karyotype is provided in section 5.4 (Incomplete Karyotype).
Chapter 6: Order of Chromosome Abnormalities in the Karyotype
A new example karyotype is provided on page 52.
Chapter 7: Normal Variable Chromosome Features
In section 7.1, the term 'variation' is defined.
Chapter 8: Numerical Chromosome Abnormalities
Two new example karyotypes have been added to section 8.2 (Sex Chromosome Abnormalities). The second example indicates that for constitutional markers, there is a space between 'mar' and 'c' in the karyotype. A new karyotype example is also presented in section 8.4 (Uniparental Disomy).
Chapter 9: Structural Chromosome Rearrangements
Several revisions were made to chapter 9 including the addition of numerous karyotype examples describing various derivative chromosomes. New karyotypes have been added to the following sections: 9.1 (General Principles), 1 additional example; 9.2.2 (Deletions), 1 additional example; 9.2.3 (Derivative Chromosomes), 3 additional examples; 9.2.4 (Dicentric Chromosomes), 1 additional example; 9.2.9 (Insertions), 2 additional examples; 9.2.11 (Isochromosomes), 1 additional example; and in 9.2.13 (Neocentromeres), 1 additional example. Several karyotypes listed in the ISCN [2005] had erroneous chromosome counts when describing derivatives involving dicentric chromosomes; those examples have been corrected in ISCN [2009] to indicate the correct 45 chromosome count (section 9.2.3). Clarification of the definition of a marker chromosome is provided in section 9.2.12. Revisions have been made to the detailed system of designating structural abnormalities in several karyotypes in section 9.2.3. It is recommended that cytogeneticists carefully review the numerous revisions in that chapter, as descriptions of derivative chromosomes have traditionally been challenging. The chapter on neoplasia has been extensively revised to include several alternative karyotypes that use either 'sdl' (sideline) or 'idem' to describe subclones. Section 11.1.4 clarifies the proper use of both 'sdl' and 'idem' for describing sidelines and has expanded explanations for some karyotypes illustrating the proper use of these terms. A new example karyotype is also present in section 11.1.3 (Mainline). It is known that cancer karyotypes can be extremely complex, and having a good understanding of the nomenclature of the examples provided can tremendously simplify report writing and interpretation. The final significant change to the ISCN [2009] is the addition of a new chapter with 55 new nomenclature examples describing copy number detection. As the field of microarray technology has advanced at a rapid pace, this section is critical for understanding how to communicate results from assays which detect gain or loss of genomic segments. The microarray nomenclature has been simplified from that which was initially described in 2005 to the symbol 'arr' which now can encompass array technology using multiple different platforms (CGH and others). Examples of normal and abnormal genomes are shown in section 14.3. The normal results are shortened over the previous designation and abnormal results again only describe specific abnormalities, leaving the assumption that all other regions gave a normal result. There is now the option to write a 'short' version, showing only the abnormal nucleotides, or a detailed version, showing normal flanking nucleotides. Because SNP arrays can reveal genotypes, nomenclature for homozygosity (hmz) and heterozygosity (htz) have been introduced. Lastly, there is now a description of how to designate nomenclature for MLPA (multiple ligation-dependent probe amplification) (section 14.4.). It is expected that as molecular technologies evolve, the nomenclature will continue to be modified to meet the needs of the cytogeneticist.
Conclusion
In conclusion, as the field of cytogenetics and molecular genetics evolves, a standardized nomenclature is critical for describing karyotypes and genomic changes accurately and concisely. This report summarizes the major changes noted in the ISCN [2009] . Cytogeneticists are encouraged to carefully review the new version and become familiar with all differences introduced. While band designations described on the idiograms appear to more precisely indicate actual bands seen at different levels of resolution, one should also be cautioned that there may be discrepancies in genomic map locations at sites described previous to the publication of the ISCN 2009 and that the idiograms and genomic browsers have not been compared and reconciled. Careful identification of these potential discrepancies is recommended and is beyond the scope of this review.
